An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs KBP 5074 (Primary)
- Indications Diabetic nephropathies; Renal hypertension
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Jul 2017.
- 30 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.